TechSeeker Profile

Celldex Therapeutics Inc (AKA: T Cell Sciences, Inc.~virus Research Institute~Avant Immunotherapeutics)
Profile last edited on: 8/23/13

Novel, disease-specific therapies induce, enhance or suppress the body's immune response.
TS Type
Small Corp
Status
Active
Year Founded
1983
Last Involved Year
N/A

Key People / Management

Location Information

Perryville III Building Suite 220 53 Frontage Road
Hampton, NJ 08827
   (908) 200-7500
   www.celldex.com

Public Profile

Celldex Therapeutics (NASDAQ:CLDX) was formed in 2008 as the result of a merger between AVANT Immunotherapeutics - which was formed following the merger of T Cell Sciences Inc and Virus Research Institute Inc in 1998 - and long time SBIR involved firm, and NJ based Celldex in 2008. Celldex Therapeutics, Inc., a biopharmaceutical company with an emphasis on developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The firm's pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Currently, the firm's pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies having the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
180
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : CLDX
Received SBIR $$
Yes

Techseeker firm in the news

There are no news available.